p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors

Triple-negative breast cancers (TNBCs) lack effective targeted therapies, and cytotoxic chemotherapies remain the standard of care for this subtype. Owing to their increased genomic instability, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are being tested against TNBCs. In particular, cli...

Full description

Bibliographic Details
Main Authors: Eduardo Cepeda Cañedo, Stephanie Totten, Ryuhjin Ahn, Paul Savage, Deanna MacNeil, Jesse Hudson, Chantal Autexier, Genevieve Deblois, Morag Park, Michael Witcher, Josie Ursini-Siegel
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-02-01
Series:JCI Insight
Subjects:
Cell biology
Oncology
Online Access:https://doi.org/10.1172/jci.insight.138382

Internet

https://doi.org/10.1172/jci.insight.138382

Similar Items